Expression of the RNA component of human telemorase (hTR) in ThinPrep® preparations from bladder washings

A. Maitra, A. Rathi, Adi F Gazdar, Arthur I Sagalowsky, R. Ashfaq

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND. The enzyme telomerase is associated with cellular immortality and is expressed in the vast majority of human neoplasms. The expression of the RNA component of human telomerase (hTR) shows excellent concordance with enzyme activity. METHODS. In this study, hTR expression was analyzed in a series of 18 perioperative bladder washings and compared with histologic diagnoses from material obtained in the same setting. The hTR expression analysis used an 35S-based in-situ hybridization assay. ThinPrep® preparations fixed in PreservCyt® solution (Cytyc Corporation, Boxborough, MA) were hybridized with sense and antisense hTR probes. A 1-4+ grading scheme was used, with appropriate positive and negative controls. RESULTS. Five of six (83%) lesions with benign histology had hTR expression that was 2+ or less in the exfoliated urothelial cells. In contrast, 11 of 12 (93%) lesions with malignant histology had an hTR expression that was focally 3+ or more, with 7 of 12 (58%) lesions having 4+ hTR expression in at least some urothelial clusters. Although increased hTR expression was present in smears with malignant urothelial cells, a similar trend was not seen with muscularis propria invasion or higher grades of TCC on subsequent histology. CONCLUSIONS. The use of in situ hybridization technique bypasses the need for stringent specimen processing and allows identification of the specific cell type that expresses telomerase

Original languageEnglish (US)
Pages (from-to)73-79
Number of pages7
JournalCancer
Volume93
Issue number1
DOIs
StatePublished - Feb 25 2001

Fingerprint

Urinary Bladder
RNA
Histology
Telomerase
In Situ Hybridization
Enzymes
Neoplasms

Keywords

  • HTR
  • Human telomerase RNA component
  • Telomerase repeat amplificaltion protocol (TRAP)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of the RNA component of human telemorase (hTR) in ThinPrep® preparations from bladder washings. / Maitra, A.; Rathi, A.; Gazdar, Adi F; Sagalowsky, Arthur I; Ashfaq, R.

In: Cancer, Vol. 93, No. 1, 25.02.2001, p. 73-79.

Research output: Contribution to journalArticle

Maitra, A. ; Rathi, A. ; Gazdar, Adi F ; Sagalowsky, Arthur I ; Ashfaq, R. / Expression of the RNA component of human telemorase (hTR) in ThinPrep® preparations from bladder washings. In: Cancer. 2001 ; Vol. 93, No. 1. pp. 73-79.
@article{a3a81c4809a44ae79fed6c6d40a4ca41,
title = "Expression of the RNA component of human telemorase (hTR) in ThinPrep{\circledR} preparations from bladder washings",
abstract = "BACKGROUND. The enzyme telomerase is associated with cellular immortality and is expressed in the vast majority of human neoplasms. The expression of the RNA component of human telomerase (hTR) shows excellent concordance with enzyme activity. METHODS. In this study, hTR expression was analyzed in a series of 18 perioperative bladder washings and compared with histologic diagnoses from material obtained in the same setting. The hTR expression analysis used an 35S-based in-situ hybridization assay. ThinPrep{\circledR} preparations fixed in PreservCyt{\circledR} solution (Cytyc Corporation, Boxborough, MA) were hybridized with sense and antisense hTR probes. A 1-4+ grading scheme was used, with appropriate positive and negative controls. RESULTS. Five of six (83{\%}) lesions with benign histology had hTR expression that was 2+ or less in the exfoliated urothelial cells. In contrast, 11 of 12 (93{\%}) lesions with malignant histology had an hTR expression that was focally 3+ or more, with 7 of 12 (58{\%}) lesions having 4+ hTR expression in at least some urothelial clusters. Although increased hTR expression was present in smears with malignant urothelial cells, a similar trend was not seen with muscularis propria invasion or higher grades of TCC on subsequent histology. CONCLUSIONS. The use of in situ hybridization technique bypasses the need for stringent specimen processing and allows identification of the specific cell type that expresses telomerase",
keywords = "HTR, Human telomerase RNA component, Telomerase repeat amplificaltion protocol (TRAP)",
author = "A. Maitra and A. Rathi and Gazdar, {Adi F} and Sagalowsky, {Arthur I} and R. Ashfaq",
year = "2001",
month = "2",
day = "25",
doi = "10.1002/1097-0142(20010225)93:1<73::AID-CNCR9010>3.0.CO;2-I",
language = "English (US)",
volume = "93",
pages = "73--79",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Expression of the RNA component of human telemorase (hTR) in ThinPrep® preparations from bladder washings

AU - Maitra, A.

AU - Rathi, A.

AU - Gazdar, Adi F

AU - Sagalowsky, Arthur I

AU - Ashfaq, R.

PY - 2001/2/25

Y1 - 2001/2/25

N2 - BACKGROUND. The enzyme telomerase is associated with cellular immortality and is expressed in the vast majority of human neoplasms. The expression of the RNA component of human telomerase (hTR) shows excellent concordance with enzyme activity. METHODS. In this study, hTR expression was analyzed in a series of 18 perioperative bladder washings and compared with histologic diagnoses from material obtained in the same setting. The hTR expression analysis used an 35S-based in-situ hybridization assay. ThinPrep® preparations fixed in PreservCyt® solution (Cytyc Corporation, Boxborough, MA) were hybridized with sense and antisense hTR probes. A 1-4+ grading scheme was used, with appropriate positive and negative controls. RESULTS. Five of six (83%) lesions with benign histology had hTR expression that was 2+ or less in the exfoliated urothelial cells. In contrast, 11 of 12 (93%) lesions with malignant histology had an hTR expression that was focally 3+ or more, with 7 of 12 (58%) lesions having 4+ hTR expression in at least some urothelial clusters. Although increased hTR expression was present in smears with malignant urothelial cells, a similar trend was not seen with muscularis propria invasion or higher grades of TCC on subsequent histology. CONCLUSIONS. The use of in situ hybridization technique bypasses the need for stringent specimen processing and allows identification of the specific cell type that expresses telomerase

AB - BACKGROUND. The enzyme telomerase is associated with cellular immortality and is expressed in the vast majority of human neoplasms. The expression of the RNA component of human telomerase (hTR) shows excellent concordance with enzyme activity. METHODS. In this study, hTR expression was analyzed in a series of 18 perioperative bladder washings and compared with histologic diagnoses from material obtained in the same setting. The hTR expression analysis used an 35S-based in-situ hybridization assay. ThinPrep® preparations fixed in PreservCyt® solution (Cytyc Corporation, Boxborough, MA) were hybridized with sense and antisense hTR probes. A 1-4+ grading scheme was used, with appropriate positive and negative controls. RESULTS. Five of six (83%) lesions with benign histology had hTR expression that was 2+ or less in the exfoliated urothelial cells. In contrast, 11 of 12 (93%) lesions with malignant histology had an hTR expression that was focally 3+ or more, with 7 of 12 (58%) lesions having 4+ hTR expression in at least some urothelial clusters. Although increased hTR expression was present in smears with malignant urothelial cells, a similar trend was not seen with muscularis propria invasion or higher grades of TCC on subsequent histology. CONCLUSIONS. The use of in situ hybridization technique bypasses the need for stringent specimen processing and allows identification of the specific cell type that expresses telomerase

KW - HTR

KW - Human telomerase RNA component

KW - Telomerase repeat amplificaltion protocol (TRAP)

UR - http://www.scopus.com/inward/record.url?scp=0035945966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035945966&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20010225)93:1<73::AID-CNCR9010>3.0.CO;2-I

DO - 10.1002/1097-0142(20010225)93:1<73::AID-CNCR9010>3.0.CO;2-I

M3 - Article

C2 - 11241269

AN - SCOPUS:0035945966

VL - 93

SP - 73

EP - 79

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -